Cryo-Cell to Donate 50,000 Face Masks to OBGYN Practices and Patients Around the Country Amidst COVID-19
Cryo-Cell International, Inc., the world’s first private use cord blood bank, announced plans to donate fifty thousand face masks to obstetrics and gynecology practices around the United States to help support healthcare professionals in safely meeting the needs of their patients during the global pandemic. In addition, a portion of these masks will be donated to pregnant women to protect them during this special time in their lives.
OLDSMAR, FLA. (PRWEB)JUNE 08, 2020
Cryo-Cell International’s announcement comes on the heel of increased demand for masks and other protective measures to protect workers in the medical field. The face masks will be distributed nationwide to obstetrical and gynecological doctors and their dedicated staffs who valiantly risk their lives every day to provide healthcare to pregnant women. The delivery of masks is scheduled to begin later this week.
In addition to face mask donations, Cryo-Cell International has and will contribute other essential supplies within the medical field including face shields, hand sanitizers, and informational pieces regarding COVID-19 for practitioners and pregnant patients alike.
David Portnoy, Cryo-Cell International’s Chairman and Co-CEO, stated, “We recognize and salute the vital role that physicians and other healthcare providers play in taking care of pregnant women, especially during the COVID-19 pandemic. In support of their noble efforts, Cryo-Cell International is proud to provide essential medical items to allow them to provide the highest quality care for their patients.”
Cryo-Cell International remains committed to providing clients with premier cord blood and cord tissue preservation service and aiding in the advancement of regenerative medicine. As research continues to develop in finding treatments for COVID-19 through the use of mesenchymal stem cells found in cord tissue, the company continues to help expecting parents protect what matters most through umbilical stem cell preservation. Cryo-Cell International anticipates ongoing plans to aid in financial contributions and personal protective equipment donations to help safeguard the efforts of essential workers in OBGYN practices around the United States during COVID-19.
About Cryo-Cell International, Inc.
Founded in 1989, Cryo-Cell International, Inc. is the world's first private cord blood bank. More than 500,000 parents from 87 countries trust Cryo-Cell to preserve their family members' stem cells. Cryo-Cell's mission is to provide clients with state-of-the-art stem cell cryopreservation services and support the advancement of regenerative medicine. Cryo-Cell operates in a facility that is FDA registered, cGMP-/cGTP-compliant, and is licensed in all states requiring licensure. Besides being AABB accredited as a cord blood facility, Cryo-Cell is also the first U.S. (for private use only) cord blood bank to receive FACT accreditation for adhering to the most stringent cord blood quality standards set by any internationally recognized, independent accrediting organization. In addition, Cryo-Cell is ISO 9001:2008 certified by BSI, an internationally recognized, quality assessment organization. Cryo-Cell is a publicly-traded company, OTCQB:CCEL. For more information, please visit http://www.cryo-cell.com. For a complete list of references, visit http://www.cryo-cell.com/references.
Statements wherein the terms "believes", "intends", "projects", "anticipates", "expects", and similar expressions as used are intended to reflect "forward-looking statements" of the Company. The information contained herein is subject to various risks, uncertainties and other factors that could cause actual results to differ materially from the results anticipated in such forward-looking statements or paragraphs, many of which are outside the control of the Company, which include future medical and research developments. The Company disclaims any obligations to subsequently revise any forward-looking statements to reflect events or circumstances after the date of such statements.
Released June 8, 2020